BioDlink International Company Limited (HKG:1875)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.890
-0.040 (-0.81%)
May 7, 2026, 4:08 PM HKT
Market Cap3.81B +144.1%
Revenue (ttm)831.99M -31.9%
Net Income-111.69M
EPS-0.15
Shares Out772.79M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume445,600
Average Volume1,609,510
Open4.860
Previous Close4.930
Day's Range4.860 - 5.030
52-Week Range1.700 - 5.870
Beta-0.11
RSI53.74
Earnings DateMar 18, 2026

About HKG:1875

BioDlink International Company Limited, an investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat advanced, metastatic or recurrent non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 613
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1875
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements